Trial Profile

Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel/ritonavir (Primary) ; Hormones
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

30 May 2024 Status changed from recruiting to discontinued.
15 Feb 2020 The number of patient is currently 19 in Part 1A and will be ≥ 9 in Part 1B as per the trial design presented at the 44th European Society for Medical Oncology Congress..
15 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com